195 related articles for article (PubMed ID: 29240024)
21. Preventing and Managing Toxicities of High-Dose Methotrexate.
Howard SC; McCormick J; Pui CH; Buddington RK; Harvey RD
Oncologist; 2016 Dec; 21(12):1471-1482. PubMed ID: 27496039
[TBL] [Abstract][Full Text] [Related]
22. Methotrexate level discrepancy post-glucarpidase: A pediatric case series and review of literature.
Kibby D; Trinkman H
Pediatr Blood Cancer; 2024 Mar; 71(3):e30831. PubMed ID: 38149827
[TBL] [Abstract][Full Text] [Related]
23. MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to Inform Post-Infusion Care and Use of Glucarpidase.
Taylor ZL; Mizuno T; Punt NC; Baskaran B; Navarro Sainz A; Shuman W; Felicelli N; Vinks AA; Heldrup J; Ramsey LB
Clin Pharmacol Ther; 2020 Sep; 108(3):635-643. PubMed ID: 32558929
[TBL] [Abstract][Full Text] [Related]
24. Reply to: Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.
Widemann BC
Pediatr Blood Cancer; 2016 Feb; 63(2):366. PubMed ID: 26488622
[No Abstract] [Full Text] [Related]
25. Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients.
Christensen AM; Pauley JL; Molinelli AR; Panetta JC; Ward DA; Stewart CF; Hoffman JM; Howard SC; Pui CH; Pappo AS; Relling MV; Crews KR
Cancer; 2012 Sep; 118(17):4321-30. PubMed ID: 22252903
[TBL] [Abstract][Full Text] [Related]
26. A second administration of glucarpidase in a different cycle of high-dose methotrexate: Is it safe and effective in adults?
Domingo-González A; Osorio S; Landete E; Monsalvo S; Díez-Martín JL
J Oncol Pharm Pract; 2021 Apr; 27(3):734-738. PubMed ID: 32731844
[TBL] [Abstract][Full Text] [Related]
27. Commentary.
Milone MC
Clin Chem; 2010 Dec; 56(12):1795-6. PubMed ID: 21119036
[No Abstract] [Full Text] [Related]
28. Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function.
Fermiano M; Bergsbaken J; Kolesar JM
Am J Health Syst Pharm; 2014 May; 71(10):793-8. PubMed ID: 24780487
[TBL] [Abstract][Full Text] [Related]
29. Reduced-dose carboxypeptidase-G2 successfully lowers elevated methotrexate levels in an adult with acute methotrexate-induced renal failure.
Trifilio S; Ma S; Petrich A
Clin Adv Hematol Oncol; 2013 May; 11(5):322-3. PubMed ID: 23880719
[No Abstract] [Full Text] [Related]
30. Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.
Meyers PA
Pediatr Blood Cancer; 2016 Feb; 63(2):364. PubMed ID: 26488216
[No Abstract] [Full Text] [Related]
31. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
[TBL] [Abstract][Full Text] [Related]
32. Reply to: Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.
Scott JR; Crews KR
Pediatr Blood Cancer; 2016 Feb; 63(2):365. PubMed ID: 26488798
[No Abstract] [Full Text] [Related]
33. Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.
Nowicki TS; Bjornard K; Kudlowitz D; Sandoval C; Jayabose S
J Pediatr Hematol Oncol; 2008 Dec; 30(12):950-2. PubMed ID: 19131789
[TBL] [Abstract][Full Text] [Related]
34. [Carboxypeptidase-G2 administration after high-dose methotrexate. Treatment and drug interactions].
Cózar Olmo JA; Martínez Colmenero C; Peláez Pleguezuelos I; Leiva Gea I; López García AB; de la Cruz Moreno J
An Pediatr (Barc); 2009 Sep; 71(3):230-4. PubMed ID: 19617010
[TBL] [Abstract][Full Text] [Related]
35. Production of "biobetter" variants of glucarpidase with enhanced enzyme activity.
Al-Qahtani AD; Bashraheel SS; Rashidi FB; O'Connor CD; Romero AR; Domling A; Goda SK
Biomed Pharmacother; 2019 Apr; 112():108725. PubMed ID: 30970523
[TBL] [Abstract][Full Text] [Related]
36. Successful Treatment of Delayed Methotrexate Clearance Using Glucarpidase Dosed on Ideal Body Weight in Obese Patients.
Krüger C; Engel N; Reinert J; Alsdorf W; Fiedler W; Dierlamm J; Bokemeyer C; Langebrake C
Pharmacotherapy; 2020 May; 40(5):479-483. PubMed ID: 32239519
[TBL] [Abstract][Full Text] [Related]
37. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
[TBL] [Abstract][Full Text] [Related]
38. Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction.
Widemann BC
Pediatr Blood Cancer; 2015 Sep; 62(9):1512-3. PubMed ID: 25940351
[No Abstract] [Full Text] [Related]
39. [Carboxypeptidase-G2-rescue in a woman with methotrexate-induced renal failure].
von Poblozki A; Dempke W; Schmoll HJ
Med Klin (Munich); 2000 Aug; 95(8):457-60. PubMed ID: 10985069
[TBL] [Abstract][Full Text] [Related]
40. Effective removal of methotrexate by high-flux hemodialysis.
Saland JM; Leavey PJ; Bash RO; Hansch E; Arbus GS; Quigley R
Pediatr Nephrol; 2002 Oct; 17(10):825-9. PubMed ID: 12376811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]